These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25558789)

  • 1. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
    N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
    Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
    Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
    Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
    Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients.
    Zhang H; Li X; Zhang Z; Huang S; Guo Q; Yan N
    Medicine (Baltimore); 2023 Jul; 102(29):e33543. PubMed ID: 37478263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
    Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib inhibition of
    Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
    Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
    Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
    Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature.
    Korkmaz M; Eryilmaz MK
    Anticancer Drugs; 2022 Jan; 33(1):e799-e801. PubMed ID: 34459458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants.
    Ohishi Y; Nakanishi Y; Hirotani Y; Suzuki A; Tanino T; Nishimaki-Watanabe H; Kobayashi H; Nozaki F; Ohni S; Tang X; Hayashi K; Nakagawa Y; Shimizu T; Tsujino I; Takahashi N; Gon Y; Masuda S
    Thorac Cancer; 2024 Jan; 15(1):89-93. PubMed ID: 38093515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer.
    Nishiyama Y; Omori S; Matsumoto H; Komiya K; Hiramatsu K
    Intern Med; 2023 Dec; 62(23):3507-3510. PubMed ID: 37062732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Targeting ROS1 in Lung Cancer.
    Lin JJ; Shaw AT
    J Thorac Oncol; 2017 Nov; 12(11):1611-1625. PubMed ID: 28818606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India.
    Gupta D; Gupta N; Singh N; Prinja S
    JCO Glob Oncol; 2024 Feb; 10():e2300260. PubMed ID: 38359374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.
    Riess JW; Nagpal S; Neal JW; Wakelee HA
    J Natl Compr Canc Netw; 2013 Apr; 11(4):389-94. PubMed ID: 23584342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Gerlinger M; Norton L; Swanton C
    N Engl J Med; 2013 Sep; 369(12):1172-3. PubMed ID: 24047073
    [No Abstract]   [Full Text] [Related]  

  • 17. Deepening the Knowledge of
    Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
    [No Abstract]   [Full Text] [Related]  

  • 18. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
    Moro-Sibilot D; Cozic N; Pérol M; Mazières J; Otto J; Souquet PJ; Bahleda R; Wislez M; Zalcman G; Guibert SD; Barlési F; Mennecier B; Monnet I; Sabatier R; Bota S; Dubos C; Verriele V; Haddad V; Ferretti G; Cortot A; De Fraipont F; Jimenez M; Hoog-Labouret N; Vassal G
    Ann Oncol; 2019 Dec; 30(12):1985-1991. PubMed ID: 31584608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iruplinalkib: First Approval.
    Keam SJ
    Drugs; 2023 Dec; 83(18):1717-1721. PubMed ID: 38008856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRUST-II: a global phase II study of taletrectinib in
    Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
    Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.